-
摘要:
随着纳武单抗（Nivolumab）被写进晚期肾癌二线治疗指南，免疫治疗再次回到晚期肾癌的治疗领域并取得成功。免疫治疗单药一线治疗的疗效有限，因而免疫联合抗血管靶向治疗成为目前的主要进展。近年来，几项大型Ⅲ期随机对照研究先后公布研究结果。Nivolumab和伊匹单抗（Ipililmumab）的免疫联合免疫治疗推荐用于中高危晚期肾癌患者。免疫联合抗血管靶向治疗中帕博利珠单抗（Pembrolizumab）联合阿昔替尼（Axitinib）以及阿维鲁单抗（Avelumab）联合Axitinib也写入指南。如何选择免疫治疗的合适人群，需要结合疾病特征、危险分层和社会经济学综合考虑，并探索合适的生物预测标志物。
Abstract:Immunotherapy has made great progress in the treatment of advanced renal cell carcinoma (RCC), since nivolumab was approved for the second-line therapy of advanced RCC. The efficacy of antiPD1 monotherapy was limited in the first-line setting, therefore the combination of immunotherapy and anti-angiogenesis targeted therapy is becoming the trend. As the release of several randomized phase Ⅲ clinical trials results, ipilimumab in combination with nivolumab is recommended for intermediate-/highrisk advanced RCC. Pembrolizumab plus axitinib or avelumab plus axitinib are proved to be more efficacious than traditional targeted therapy. How to select the appropriate population for immunotherapy depends on individual characteristics, disease risk, social economics and appropriate prognostic biomarkers.
-
Key words:
- Advanced renal cell carcinoma /
- Immunotherapy /
- Biomarker
-
作者贡献周莉：搜集和整理文献数据、撰写文章盛锡楠：构思和设计整体文章思路
-
[1] Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 3: 17009. doi: 10.1038/nrdp.2017.9
[2] Kumar R, Kapoor A. Current management of metastatic renal cell carcinoma: evolving new therapies[J]. Curr Opin Support Palliat Care, 2017, 11(3): 231-237. doi: 10.1097/SPC.0000000000000277
[3] Bedke J, Gauler T, Grünwald V, et al. Systemic therapy in metastatic renal cell carcinoma[J]. World J Urol, 2017, 35(2): 179-188. doi: 10.1007/s00345-016-1868-5
[4] Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2015, 373(19): 1803-1813. doi: 10.1056/NEJMoa1510665
[5] Escudier B, Motzer RJ, Sharma P, et al. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025[J]. Eur Urol, 2017, 72(3): 368-376. doi: 10.1016/j.eururo.2017.03.037
[6] Choueiri TK, Fishman MN, Escudier B, et al. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma[J]. Clin Cancer Res, 2016, 22(22): 5461-5471. doi: 10.1158/1078-0432.CCR-15-2839
[7] Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial[J]. Lancet Oncol, 2018, 19(3): 405-415. doi: 10.1016/S1470-2045(18)30081-0
[8] Hammers HJ, Plimack ER, Infante JR, et al. Safety and Efficacy of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study[J]. J Clin Oncol, 2017, 35(34): 3851-3858. doi: 10.1200/JCO.2016.72.1985
[9] Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2018, 378(14): 1277-1290. doi: 10.1056/NEJMoa1712126
[10] Marc-Oliver G, Manuela S, Ignacio D, et al. Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC)[J]. Ann Oncol, 2019, 30(Suppl_5): Abstract LBA57. http://cn.bing.com/academic/profile?id=4e0ca889b7d1c8cca1a772bc767d7c32&encoded=0&v=paper_preview&mkt=zh-cn
[11] Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2019, 380(12): 1116-1127. doi: 10.1056/NEJMoa1816714
[12] Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2019, 380(12): 1103-1115. doi: 10.1056/NEJMoa1816047
[13] McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma[J]. Nat Med, 2018, 24(6): 749-757. doi: 10.1038/s41591-018-0053-3
[14] Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial[J]. Lancet, 2019, 393(10189): 2404-2415. doi: 10.1016/S0140-6736(19)30723-8
[15] Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial[J]. Lancet, 2011, 378(9807): 1931-1939. doi: 10.1016/S0140-6736(11)61613-9
[16] Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(6): 552-562. doi: 10.1016/S1470-2045(13)70093-7
[17] Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-cell Carcinoma[J]. N Engl J Med, 2015, 373(19): 1814-1823. doi: 10.1056/NEJMoa1510016
[18] Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-cell Carcinoma (METEOR): final results from a randomized, open-label, phase 3 trial[J]. Lancet Oncol, 2016, 17(7): 917-927. doi: 10.1016/S1470-2045(16)30107-3
[19] Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus Sunitinib as Initial Targeted Therapy for Patients with Metastatic Renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial[J]. J Clin Oncol, 2017, 35(6): 591-597. doi: 10.1200/JCO.2016.70.7398
[20] McGregor BA, Lalani AK, Xie W, et al. Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)[J]. Ann Oncol, 2019, 29(suppl_8): Abstract 879P.
[21] Auvray M, Auclin E, Barthelemy P, et al. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma[J]. Eur J Cancer, 2019, 108: 33-40. doi: 10.1016/j.ejca.2018.11.031
[22] Yasser Ged. Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF)[J]. J Clin Oncol, 2019, 37(suppl): Abstract 4576. http://cn.bing.com/academic/profile?id=64505a7bf4e5d0a4ccd3b15c86517cb2&encoded=0&v=paper_preview&mkt=zh-cn
计量
- 文章访问数: 2592
- HTML全文浏览量: 520
- PDF下载量: 2112
下载:
